{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:39:09Z","timestamp":1761896349170,"version":"build-2065373602"},"reference-count":31,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2016,8,12]],"date-time":"2016-08-12T00:00:00Z","timestamp":1470960000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2016,11]]},"abstract":"\n Aims<\/jats:title>\n \n To predict individualized treatment effects of angiotensin receptor blockers (\n ARBs<\/jats:styled-content>\n ) on cardiovascular and renal complications in order to help clinicians and patients assess the benefit of treatment (or adherence) and estimate remaining disease risk.\n <\/jats:p>\n <\/jats:sec>\n \n Materials and methods<\/jats:title>\n \n In patients with diabetic nephropathy, the 3\u2010year treatment effect of\n ARBs<\/jats:styled-content>\n was predicted in terms of absolute risk reduction (\n ARR<\/jats:styled-content>\n ) for end\u2010stage renal disease (\n ESRD<\/jats:styled-content>\n ) and cardiovascular disease (\n CVD<\/jats:styled-content>\n ; i.e. myocardial infarction, stroke, hospitalization for heart failure) and all\u2010cause mortality. Competing\u2010risk\u2010adjusted proportional hazard models were developed based on the\n I<\/jats:styled-content>\n rbesartan\n D<\/jats:styled-content>\n iabetic\n N<\/jats:styled-content>\n ephropathy\n T<\/jats:styled-content>\n rial (\n IDNT<\/jats:styled-content>\n ) and externally validated in the\n R<\/jats:styled-content>\n eduction of\n E<\/jats:styled-content>\n ndpoints\n NIDDM<\/jats:styled-content>\n with\n A<\/jats:styled-content>\n ngiotensin\n II A<\/jats:styled-content>\n ntagonist\n L<\/jats:styled-content>\n osartan (\n RENAAL<\/jats:styled-content>\n ) trial.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Predictors included in the model were age, sex, smoking sex, systolic blood pressure, urinary albumin\/creatinine ratio, estimated glomerular filtration rate, albumin and phosphorus. The median predicted 3\u2010year risk without treatment was 6.0% for\n ESRD<\/jats:styled-content>\n and 28.0% for\n CVD<\/jats:styled-content>\n and mortality. The median [interquartile range (\n IQR<\/jats:styled-content>\n )] predicted 3\u2010year\n ARR<\/jats:styled-content>\n was 1.2 (0.4\u20103.1)% for\n ESRD<\/jats:styled-content>\n and 2.2 (1.8\u20102.6)% for\n CVD<\/jats:styled-content>\n and mortality, resulting in a combined\n ARR<\/jats:styled-content>\n of 3.4 (2.4\u20105.5)%. The remaining disease risk was 4.7 (\n IQR<\/jats:styled-content>\n 1.7\u201012.8)% for\n ESRD<\/jats:styled-content>\n and 25.8% (\n IQR<\/jats:styled-content>\n 20.3\u201031.9)% for\n CVD<\/jats:styled-content>\n and mortality.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n The combined effects of\n ARBs<\/jats:styled-content>\n on\n ESRD<\/jats:styled-content>\n and\n CVD<\/jats:styled-content>\n and mortality in patients with diabetic nephropathy vary considerably between patients. A substantial proportion of patients remain at high risk for both outcomes despite\n ARB<\/jats:styled-content>\n treatment.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/dom.12708","type":"journal-article","created":{"date-parts":[[2016,6,23]],"date-time":"2016-06-23T08:32:52Z","timestamp":1466670772000},"page":"1120-1127","source":"Crossref","is-referenced-by-count":12,"title":["Individualized prediction of the effect of angiotensin receptor blockade on renal and cardiovascular outcomes in patients with diabetic nephropathy"],"prefix":"10.1111","volume":"18","author":[{"given":"N. G. C.","family":"van der Sande","sequence":"first","affiliation":[{"name":"Department of Vascular Medicine University Medical Center Utrecht Utrecht The Netherlands"},{"name":"Department of Nephrology and Hypertension University Medical Center Utrecht Utrecht The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. A. N.","family":"Dorresteijn","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine University Medical Center Utrecht Utrecht The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. L. J.","family":"Visseren","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine University Medical Center Utrecht Utrecht The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. P.","family":"Dwyer","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension Vanderbilt University Medical Center Nashville Tennessee"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. J.","family":"Blankestijn","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Hypertension University Medical Center Utrecht Utrecht The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"van der Graaf","sequence":"additional","affiliation":[{"name":"Julius Centre for Health Sciences and Primary Care University Medical Center Utrecht Utrecht The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. L. J.","family":"Heerspink","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology University Medical Center Groningen, University of Groningen Groningen The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,8,12]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011303"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs075"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5888"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2014.12.046"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2014-306342"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.451"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2008.04.026"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2010.07.016"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011161"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1999.10474144"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2007.07.006"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2011.07.016"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01381005"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-11-85"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006257"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2006.01.014"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-77244-8"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0b013e3181a39056"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btr511"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra050100"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e318235eb4d"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc07-9917"},{"key":"e_1_2_5_24_1","first-page":"2","article-title":"KDIGO Clinical practice guideline for the evaluation and management of chronic kidney disease foreword","volume":"3","author":"Kasiske BL","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12583"},{"key":"e_1_2_5_26_1","unstructured":"Janssen Research & Development LLC.A Randomized double\u2010blind event\u2010driven placebo\u2010controlled multicenter study of the effects of canagliflozin on renal and cardiovascular outcomes in subjects with type 2 diabetes mellitus and diabetic Nephropathy.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02065791NLM Identifier: NCT02065791. Published 2015. Accessed January 4 2016."},{"key":"e_1_2_5_27_1","unstructured":"BayerA.Randomized double\u2010blind placebo\u2010controlled parallel\u2010group multicenter event\u2010driven phase 3 study to investigate the safety and efficacy of finerenone in addition to standard of care on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02540993NLM Identifier: NCT02540993. Published 2013. Accessed January 4 2016."},{"key":"e_1_2_5_28_1","unstructured":"AbbVie.A randomized multicountry multicenter double\u2010blind parallel placebo\u2010controlled study of the effects of atrasentan on renal outcomes in subjects with type 2 diabetes and Nephropathy SONAR: study of diabetic Nephropathy with atrasentan.https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT01858532NLM Identifier: NCT01858532. Published 2014. Accessed April 4 2016."},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.18202"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gft445"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/1470320311434818"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60739-3"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12708","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12708","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T02:34:56Z","timestamp":1761878096000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,12]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["10.1111\/dom.12708"],"URL":"https:\/\/doi.org\/10.1111\/dom.12708","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"type":"print","value":"1462-8902"},{"type":"electronic","value":"1463-1326"}],"subject":[],"published":{"date-parts":[[2016,8,12]]}}}